GB2427157A - Coated microspheres - Google Patents
Coated microspheres Download PDFInfo
- Publication number
- GB2427157A GB2427157A GB0612104A GB0612104A GB2427157A GB 2427157 A GB2427157 A GB 2427157A GB 0612104 A GB0612104 A GB 0612104A GB 0612104 A GB0612104 A GB 0612104A GB 2427157 A GB2427157 A GB 2427157A
- Authority
- GB
- United Kingdom
- Prior art keywords
- microsphere
- agent
- layer
- microspheres
- functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 356
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 152
- 239000002346 layers by function Substances 0.000 claims abstract description 130
- 238000000576 coating method Methods 0.000 claims abstract description 122
- 239000011248 coating agent Substances 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 114
- 239000010410 layer Substances 0.000 claims abstract description 101
- 239000007787 solid Substances 0.000 claims abstract description 99
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000011230 binding agent Substances 0.000 claims abstract description 49
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000012636 effector Substances 0.000 claims abstract description 34
- 239000007822 coupling agent Substances 0.000 claims abstract description 31
- 229910052759 nickel Inorganic materials 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 239000002253 acid Substances 0.000 claims abstract description 22
- 238000004873 anchoring Methods 0.000 claims abstract description 22
- 239000011521 glass Substances 0.000 claims abstract description 22
- 230000002285 radioactive effect Effects 0.000 claims abstract description 21
- 230000037452 priming Effects 0.000 claims abstract description 20
- 239000003973 paint Substances 0.000 claims abstract description 16
- 229910052742 iron Inorganic materials 0.000 claims abstract description 14
- 229920001577 copolymer Polymers 0.000 claims abstract description 12
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001400 block copolymer Polymers 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 239000000919 ceramic Substances 0.000 claims abstract description 9
- 229920001059 synthetic polymer Polymers 0.000 claims abstract description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 8
- 229920005615 natural polymer Polymers 0.000 claims abstract description 8
- 230000005298 paramagnetic effect Effects 0.000 claims abstract description 7
- 239000000049 pigment Substances 0.000 claims abstract description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002105 nanoparticle Substances 0.000 claims abstract description 6
- 229910000859 α-Fe Inorganic materials 0.000 claims abstract description 5
- 108090001008 Avidin Proteins 0.000 claims abstract description 4
- 102000004190 Enzymes Human genes 0.000 claims abstract description 4
- 108090000790 Enzymes Proteins 0.000 claims abstract description 4
- 102000004856 Lectins Human genes 0.000 claims abstract description 4
- 108090001090 Lectins Proteins 0.000 claims abstract description 4
- 239000011616 biotin Substances 0.000 claims abstract description 4
- 229960002685 biotin Drugs 0.000 claims abstract description 4
- 235000020958 biotin Nutrition 0.000 claims abstract description 4
- 150000004676 glycans Chemical class 0.000 claims abstract description 4
- 239000002523 lectin Substances 0.000 claims abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 4
- 239000011777 magnesium Substances 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 229920001184 polypeptide Polymers 0.000 claims abstract description 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 4
- 239000005017 polysaccharide Substances 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 239000003352 sequestering agent Substances 0.000 claims abstract description 4
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 4
- 239000010703 silicon Substances 0.000 claims abstract description 4
- 229910052596 spinel Inorganic materials 0.000 claims abstract description 4
- 239000011029 spinel Substances 0.000 claims abstract description 4
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 3
- 239000000956 alloy Substances 0.000 claims abstract description 3
- 229940044173 iodine-125 Drugs 0.000 claims abstract description 3
- 229910052741 iridium Inorganic materials 0.000 claims abstract description 3
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000012860 organic pigment Substances 0.000 claims abstract description 3
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 3
- 229910052705 radium Inorganic materials 0.000 claims abstract description 3
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 230000021148 sequestering of metal ion Effects 0.000 claims abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims abstract 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000004411 aluminium Substances 0.000 claims abstract 3
- 229910052782 aluminium Inorganic materials 0.000 claims abstract 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000010936 titanium Substances 0.000 claims abstract 3
- 229910052719 titanium Inorganic materials 0.000 claims abstract 3
- 229910052726 zirconium Inorganic materials 0.000 claims abstract 3
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 33
- 229920000159 gelatin Polymers 0.000 claims description 28
- 235000019322 gelatine Nutrition 0.000 claims description 28
- 239000002243 precursor Substances 0.000 claims description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000151 deposition Methods 0.000 claims description 12
- 239000001828 Gelatine Substances 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 229910000077 silane Inorganic materials 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004848 polyfunctional curative Substances 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 5
- 102000007562 Serum Albumin Human genes 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000009388 chemical precipitation Methods 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 229910000078 germane Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 230000005291 magnetic effect Effects 0.000 abstract description 22
- 238000000926 separation method Methods 0.000 abstract description 12
- 229910052792 caesium Inorganic materials 0.000 abstract description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 abstract description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 abstract 1
- 150000004032 porphyrins Chemical class 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 90
- 239000000377 silicon dioxide Substances 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000002245 particle Substances 0.000 description 23
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 108010010803 Gelatin Proteins 0.000 description 17
- 239000008367 deionised water Substances 0.000 description 17
- 239000008273 gelatin Substances 0.000 description 17
- 235000011852 gelatine desserts Nutrition 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000012491 analyte Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 210000003250 oocyst Anatomy 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- -1 microballoon Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000223935 Cryptosporidium Species 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000005388 borosilicate glass Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 230000005381 magnetic domain Effects 0.000 description 3
- 230000005389 magnetism Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000005524 ceramic coating Methods 0.000 description 2
- 239000012707 chemical precursor Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004114 Ammonium polyphosphate Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000008575 Iron Assay Methods 0.000 description 1
- 229910000708 MFe2O4 Inorganic materials 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- YBLFGGYJBKJICD-UHFFFAOYSA-N O=C=[SiH2] Chemical compound O=C=[SiH2] YBLFGGYJBKJICD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YIYFFLYGSHJWFF-UHFFFAOYSA-N [Zn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Zn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 YIYFFLYGSHJWFF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019826 ammonium polyphosphate Nutrition 0.000 description 1
- 229920001276 ammonium polyphosphate Polymers 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- YENOLDYITNSPMQ-UHFFFAOYSA-N carboxysilicon Chemical compound OC([Si])=O YENOLDYITNSPMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 229940090961 chromium dioxide Drugs 0.000 description 1
- IAQWMWUKBQPOIY-UHFFFAOYSA-N chromium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Cr+4] IAQWMWUKBQPOIY-UHFFFAOYSA-N 0.000 description 1
- AYTAKQFHWFYBMA-UHFFFAOYSA-N chromium(IV) oxide Inorganic materials O=[Cr]=O AYTAKQFHWFYBMA-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- YBRNUJSXEIBYFU-UHFFFAOYSA-N hydroxy(phenyl)silane Chemical compound O[SiH2]C1=CC=CC=C1 YBRNUJSXEIBYFU-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- OJTMBXWTXBFVQN-UHFFFAOYSA-N iron;1,10-phenanthroline Chemical compound [Fe].C1=CN=C2C3=NC=CC=C3C=CC2=C1 OJTMBXWTXBFVQN-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000007974 melamines Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002331 radioactive microsphere Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- XQMTUIZTZJXUFM-UHFFFAOYSA-N tetraethoxy silicate Chemical compound CCOO[Si](OOCC)(OOCC)OOCC XQMTUIZTZJXUFM-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C3/00—Treatment in general of inorganic materials, other than fibrous fillers, to enhance their pigmenting or filling properties
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C3/00—Treatment in general of inorganic materials, other than fibrous fillers, to enhance their pigmenting or filling properties
- C09C3/006—Combinations of treatments provided for in groups C09C3/04 - C09C3/12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/42—Magnetic properties
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Preparation (AREA)
Abstract
A microsphere comprises a core, an intermediate functional layer and an outer solid oxide coating. The core which may be buoyant, preferably hollow may comprises a synthetic polymer, a natural polymer, a co-polymer, a block co-polymer, polymethylmethacrylic acid, a protein, a glass, a ceramic or a ceramic oxide. The functional layer may be laid down as nanoparticles and may comprise a magnetizable agent such as a paramagnetic agent, a superparamagnetic agent, iron, nickel, iron oxide, a spinel ferrite or an alloy, a fluorescent or coloured agent such as a pigment, paint, polymeric organic pigment or porphyrin or a radioactive agent such as iodine-125, iodine 131, palladium, radium, iridium or caesium. The solid oxide coating may be less than 25 microns such as 0.2 to 100nm and may comprise an oxide of aluminium, titanium, silicon, magnesium or zirconium. Priming layers, anchoring agents such as functional binding agents and coupling agents may be used. An effector agent such as a protein, an antibody, a lectin, an enzyme, a polypeptide, a nucleotide, a polysaccharide, a metal -ion sequestering agent, biotin or avidin may be present on the outer surface of the solid oxide coating. The invention provides a more robust microsphere that can be used without any or limited damage to the functional layer and may be manipulated in a magnetic field, injected into a body, used in separation procedure or sprayed from a paint gun.
Description
40/65096G32 1 Coated Microspheres
Field of the invention
The present invention relates to microspheres that include a functional layer, more particularly, but not exclusively, to microspheres that include a coloured, a fluorescent, a radioactive or a magnetizable layer. Such microspheres are useful for incorporating into paints, for constructing microspheres that may be used in separation procedures, or for use in methods of treating disorders such as cancer. The invention also relates to methods for making such microspheres.
Background to the invention
Microspheres that include a layer that covers the core of the microsphere in order to provide the microsphere with a specific function are used in many fields of technology.
: *. The term microsphere' is used herein as a synonym for microcapsule, microparticle, microballoon, and microsphere particles. S...
:::* For example, microspheres that include a functional layer comprising a magnetizable agent can be used as the solid phase in separation methods. The layer of magnetizable agents enables the microspheres to be selectively recovered (and so selectively recover any analyte bound to the microspheres) from the sample in which an analyte is present by * 25 manipulation in a magnetic field. Thus, magnets may he used to selectively recover the microspheres from a liquid sample comprising the analyte. Under the appropriate optimal conditions the recovery is quantitative.
Microspheres that include a functional layer comprising a radioactive substance can be used in methods for treating disorders such as proliferative disorders. By targeting the binding of microspheres comprising such a radioactive layer to, for example, cancer cells, the radioactive microsphere may be used to selectively kill cancer cells in the body of a patient.
Microspheres that include a functional layer comprising a coloured or fluorescent agent 40/65096GE2 2 can be used as the basis for the preparation of paints, as components of cosmetic formulations, as tracers, for example in flow- visualization, and in diagnostics.
Unfortunately, however, due to the nature of the substances that are normally used to provide a functional layer (such as magnetizable agents, coloured agents, fluorescent agents and radioactive agents), these layers are poorly retained by the core of the microspheres. It has been found that such functional layers are easily stripped from microsphere cores by the physical forces that are exerted on the microspheres when in use.
For example, the forces exerted on microspheres as they are propelled from the nozzle of a paint spray gun are sufficiently high so as to strip any layer of coloured or fluorescent agent that may cover the core of the microspheres. The loss of such layers results in a ::. deterioration, or eradication, of the colour delivered by the paint to the surface being * . painted. S...
:*::* 20 It is also important for the structure of a microsphere that includes a functional layer S..
comprising a radioactive agent or a magnetizable agent to be particularly robust. Any * :. weakness in the attachment of a magnetizable layer or radioactive layer to the core of a * microsphere seriously adversely affects the ability for such a microsphere to act as an effective solid phase in a separation method or as a therapeutic.
As well as attaching a functional layer to the core of microspheres for use in a separation procedure or a method of treatment, such microspheres may be modified so as to selectively bind to a selected analyte (e.g. by binding, to the surface of the microspheres, an agent with a high level of affinity for the selected analyte). It has, however, been found that after covering a microsphere with a layer of a functional agent it is difficult to modify the microsphere so that it selectively binds to a selected analyte, e.g. by binding an agent with a high level of affinity for the selected analyte to the surface of the coated microsphere. Previous attempts to bind agents with a high level of affinity for the analyte 40/65096GB2 3 to a coated microsphere have resulted in a low density of such agents deposited on the surface of the microsphere. Additionally, only a poor level of attachment of the functional agent to the core is achieved so that the functional layer may be easily ripped from the microsphere. In the case of microspheres with a functional layer comprising a radioactive agent, detachment of the radioactive agent from the microsphere can result in serious side-effects for the patient being treated. When detached from the microsphere.
the radioactive agent will no longer selectively attack, for example, cancer cells. In the case of microspheres with a functional layer comprising a magnetizable agent, the detachment of the magnetizable layer would render it difficult to manipulate the microspheres using magnetic fields or to retain any agents that are attached to the microsphere via the magnetizable agents.
The importance of the robustness of construction of microspheres used in separation methods will be appreciated from a consideration of the physical conditions to which the microspheres may be subjected to in, for example, routine diagnostic applications. This S...
point can be illustrated by reference to the following example of Cryptosporidium parvum oocyst recovery.
Microspheres made of borosilicate glass and with a buoyant density lower than that of : water, when covered with an antibody that recognizes a Ciypiosporidiurn parvum oocyst : 25 surface antigen, may be used for selectively extracting Ciyptosporidium parvum oocysts from a sample. Crvpiosporidium parvum is a recognized parasite of humans. The oocyst, radius 5.tm, is a massive ligand and the implication of this from simple physical considerations, is that (antibody mediated) binding of an oocyst to the surface of a microsphere places a very high stress loading on the surface. indeed, if the magnetizable agent! antibody layer is not sufficiently robustly assembled then the applied torque is sufficient to tear the magnetizable agent/antibody layer from the surface of the underlying glass microsphere. Indeed, it has been found that use of such ill-formed microspheres under the conditions of a typical Crypiosporidium oocyst detection assay, results in considerable loss of the magnetizable agent /antibody material (plus associated oocysts) from the microsphere, where it will be seen as a pellet of debris at the bottom of the 40/65096GB2 4 sample tube, separated from the buoyant microspheres cores. It is then impossible to either separate the oocysts from the pellet, or attempt to detect them from among the pellet.
Accordingly, it is an object of the present invention to provide a more robust microsphere that is able to be used without any or limited damage to the functional layer of the microsphere. It is an additional object of the present invention to provide a method for making such microspheres.
Summary of the invention
The present invention describes novel microspheres that comprise a functional layer, and novel methods for making such coated microspheres, which are sufficiently robust to, for example, enable them to be manipulated in a magnetic field (when a functional layer of a magnetizable agent is incorporated into the microsphere), be injected into a body (when a functional layer of a radioactive agent is incorporated in to the microsphere), be used in a * separation procedures (when a layer of an effector molecule, such as an antibody, is ** incorporated into the microsphere), or be sprayed from a paint gun (when a functional layer of a coloured or fluorescent agent is incorporated into the microsphere), without damage to the integrity of the microsphere structure.
* .: 25 The key to the robust nature of the microspheres of the present invention is that they include a solid oxide coating. This solid oxide coating is capable of retaining materials that are provided as intermediate layers between the solid oxide coating and the core, and of acting as a structure through which subsequent "layers" (such as a layer comprising an effector agent such as an antibody) may be bound firmly to the microsphere. Thus, the tbrces exerted on the functional layers by, for example, a magnetic field, or the forces exerted on any other agents hound to the core via the solid oxide coating(i.e. effector agents such as antibodies), are not able to strip the functional layer from the core.
40/65096GB2 5 Thus, according to the first aspect of the present invention, there is provided a microsphere comprising a core, a functional layer and a solid oxide coating, wherein the functional layer forms an intermediate layer between the core and the solid oxide coating.
It is a preferred embodiment of the present invention that the solid oxide coating is substantially continuous over the surface of the microsphere and thus forming a structure whose integrity is not-dependent upon an anchorage to tile underlying layer. Thus the oxide coating is conceived as an enclosing procedure to seal in one or more underlying components, comprising the functional layer that may merely cover the surface of the microsphere core and may not he chemically bonded to it. This invention therefore finds particular application for enclosing functional agents where chemical bonding would substantially change their properties in an undesirable manner. For example, chemical attachment of pigment molecules to a surface may change their UV-visible absorption : ** spectra, and hence unfavourably change, or eliminate the colour properties of said pigment. The solid oxide coating may, therefore, act as a retaining layer.
The solid oxide coating is preferably less than 25, 20, 15, or 5 pm thick. 4**
S
However, in a preferred embodiment of the current invention, ultrathin coatings are applied, that is, coatings that are no more that 100 nm thick, and may be as little as 0.2 25 nm thick. Such coatings may be applied either by slow continuous addition, or by batchwise addition in a single cycle, as described later.
It has been found that these relatively thin layers of solid oxide coating are still able to provide a substantially continuous coating of the microsphere such that the functional layer is retained below the solid oxide coating and is shielded from adverse reactions with substances in the environment in which the microsphere is placed. Surprisingly, such thin layers have the advantage that they present an increased surface area than microspheres constructed with a relatively thick solid oxide coating. Without wishing to be bound by theory, but in the interests of clarity, it would appear that functional layers, e.g. of superparamagnetic oxide nanoparticles (diameter < 100 nm) tend to produce a 40/65096GB2 6 rough finish to the microspheres, and when these layers are coated with a relatively thick layer of solid oxide (> 100 nm) the valleys and troughs that define this rough outer surface become buried within the smooth oxide coating. However, a thin layer of solid oxide coating retains the valleys and troughs established by the functional layer on the outer surface of the coated microsphere, thereby providing a large external surface area.
Such a large surface area is beneficial. For example, a large surface area means that one can bind more ligands to the outer surface of the microspheres. A further advantage is that a thin, rather than thick, solid oxide layer will have less of an effect on the perceived intensity or colour of any functional layer.
Thus, in a preferred example of the present invention, the sold oxide coating may be less than I OOnm thick, preferably from 0.2 to 100, more preferably from 0.2 to 50 nm thick.
Such thicknesses correspond roughly to between 1 complete and 100 complete molecular layers and correspond to between roughly 0.05% and 5% the mass of the final coated * S..
microsphere.
The functional layer may be directly associated with the core and/or the solid oxide coating. Alternatively, intermediate layers may exist between the core and the functional layer and/or between the functional layer and the solid oxide coating.
* 25 Where the precursor has an affinity for the functional layer (e.g. in the case of TEOS and magnetite) a priming layer may not be required. However, particularly where there is no or little affinity between the precursor, and the functional layer (e.g. in the case of TEOS and smooth silver-coated microspheres) it has been found that optimisation of the quality of the solid oxide coating (defined in terms of percentage surface area covering and thickness of deposited coating) may be achieved if the microsphere surface is first primed to accept the solid oxide coating. Accordingly, it is an embodiment of the present invention that the microsphere further comprises a priming layer, wherein the priming layer forms an intermediate layer between the solid oxide coating and the functional layer. The priming layer and the solid oxide coating may be directly associated with each other. The priming layer may be chemically attached to the functional layer via a 40/65096GB2 7 coupling agent, or it may simply be a coating, held in place by weak electrostatic and/or hydrophobic interactions.
The inventors have unexpectedly found that certain priming agents, such as gelatine, facilitate the dispersion of particles in the solvent for the subsequent solid oxide coating step. This is important because it prevents aggregation, and hence the formation of polymeric solid oxide coated particles, especially where that particle to be coated is substantially hydrophobic.
The microsphere may further comprise an anchoring agent, wherein the functional layer is anchored to the core by binding to the anchoring agent.
Because of the nature of the substances that are useful for constructing functional layers (i.e. magnetizable agents such as elemental nickel, or a pigment compound) , functional s..
* * layers are not usually able to chemically bind to materials conventionally used for * 20 making the core of microspheres, for example an inorganic material such as borosilicate * glass or an inert polymer such as PVC. However, it has been found that by providing an anchoring agent as an intermediate between the core and the functional layer it is possible to chemically hind the functional layer to the core via this intermediate, thereby providing * :. a more secure attachment than could be achieved by simply physically coating the core * 25 with a functional layer.
The anchoring agent may comprise a functional-layer binding agent (e.g. a protein such as gelatine) which binds to the functional layer. Depending on the material used to make the core and the choice of functional-layer binding agent, the functional-layer binding agent may be able to bind directly to the core. However, the functional-layer binding agent may be bound to the core by a coupling agent (e.g. a silane). Therefore, in one embodiment of the present invention, the anchoring agent further comprises a coupling agent which couples the functional-layer binding agent to the core.
The functional layer may bind directly to the functional-layer binding agent.
40/65096GB2 8 Alternatively, the functional layer can be coupled to the functional-layer binding agent by a coupling agent (such as a silane).
The microspheres of the present invention may comprise further layers that are external to the solid oxide coating. For example, microspheres that are prepared for use in a separation procedure can be adapted in order to capture a specific analyte, or microspheres that are prepared for treating a disorder can be adapted in order to bind to a specific target (i.e. a cancer cell), by binding an effector agent to the outer surface of the microsphere (e.g. an agent that has specific affinity for the analyte or target).
Additionally, microspheres that are prepared for paint may include a coloured agent 1 5 attached to the external surface. Such microspheres may he used as the basis for colour change paints; the externally attached colour agent may, over time, be removed from the microsphere by environmental factors leaving the microspheres to reflect only, for example, the colour of a colour agent (i.e. functional layer) trapped beneath the solid I...
oxide coating. 20
Thus, in one embodiment of the present invention the microspheres comprise an effector agent, wherein the solid oxide coating forms an intermediate layer between the effector agent and the core. The effector agent may be directly associated with the solid oxide coating, or may be coupled to the solid oxide coating by a coupling agent (e.g. a silane).
Alternatively, one or more layers may be interposed between the effector agent and the solid oxide coating.
Microspheres that have as their outer layer a coating of a solid oxide are also of use in a number of applications. For example, when the functional layer is a coloured or fluorescent layer trapped beneath the solid oxide coating, the microspheres may be useful for incorporating into paints and may not require any layer that is external to the solid oxide coating. It is also useful to produce microspheres for use in a separation protocol that have not been adapted in order to capture a specific analyte. Providing such "blank" microspheres gives the skilled person the ability to bind the appropriate effector agent (e.g. by the methods described below) for capturing the target analyte in any specific 40/65096G32 9 separation protocol. With such applications in mind, the continuous or near continuous oxide coating confers the additional benefit of acting as a robust substratum for the incorporation of an appropriate effector layer. Methods for binding effector molecules to an oxide surfaces are well-described in the prior-art and can be straightforwardly applied to the present structure by those skilled in the art.
As mentioned above, functional layers applied to the core of a microsphere can easily be stripped from the core by various physical forces that are exerted on the microspheres when in use. However, it has been found that it is possible to construct microspheres that do not suffer from this problem by applying a coating of a solid oxide to the microspheres after the functional layer has been deposited on the core.
Thus, according to a second aspect of the present invention there is provided a method for preparing a microsphere comprising the steps of depositing a functional layer on a microsphere core prior to coating the microsphere with a solid oxide. s 20
* : *: :* Any method of depositing a functional layer on a core would be appropriate for use in the method of the present invention. For example, the functional layer may be deposited by electrolytic or electroless deposition, by chemical precipitation, by chemical bonding, by : : 25 spray-drying or by vapour phase coating.
Any method of applying the solid oxide coating would be appropriate for use in the method of the present invention. For example, the solid oxide coating may be applied by chemical precipitation. Preferably, the solid oxide coating is laid down by a sol-gel method. In such methods a chemical precursor or mixture of chemical precursors of the solid oxide are hydrolysed and so pass sequentially through a solution state and gel state before being dehydrated to a glass or ceramic. The solid oxide may be precipitated from an appropriate precursor of the solid oxide using the sol-ge! approach. Methods for laying down of solid oxide coatings are known in the prior art. For example International Publication No. WO 98/12717 (to Merck) discloses one method for coating particles with 40/65096GB2 10 a solid silica layer, and US 6110 528 to Kimura similarly discloses one method for coating particles with titanium dioxide (titania) layer.
For example, layers of silica can he grown by mixing a silica precursor such as tetraethoxyorthosilane (TEOS) in an appropriate solvent. Under optimal conditions the precursor migrates to the particle surface and polymerises to form a hydrated silica coat.
The recovered particles are then heat-cured to form the final anhydrous silica shell.
The exact conditions of the initial coating reaction are selected to ensure that the precursor migrates to the surface of the microsphere, and to minimise self-aggregation in the solvent, which gives rise to unwanted amorphous silica particles. Variables in the optimization procedure include the exact solvent composition and the temperature and the rate of addition of the precursor (from an external reservoir, in an appropriate solvent). Both the reservoir concentration of the precursor and the rate of addition can be manipulated to control the growth process. In general it is found that lower rates of addition, and lower concentrations favour growth of stable, smooth silica layers, whilst high concentrations and rates favour "chaotic" growth, leading to rough, uneven surfaces.
As an alternative to continuous addition, the precursor may be added batchwise in order : . to build up a shell of any desired final thickness.
The step of applying the solid oxide coating is preferably controlled in order to deposit a coating of pre-determined thickness (e.g. the preferred thicknesses described above). For example, control of the amount of solid oxide precursor that is added during the step of coating the microsphere in a solid oxide coating will control the thickness of that coating.
The precursor is preferably a low molecular-weight precursor of the solid oxide. For the avoidance of doubt a low molecular-weight molecule is one that has a molecular weight of 1000 amu or less. The skilled person would be aware of the appropriate precursors that could be used to lay down any chosen solid oxide coating. For example, if one is to lay down a silica coating then an alkoxysilane such as tetraethoxyorthosilane would be an 40/65096G32 11 appropriate precursor. When laying down a titania coating, an alkoxytitanate such as tetraethoxyorthotilanate would be an appropriate precursor.
The coating of the microsphere with solid oxide is preferably carried out by adding an oxide precursor to a mixture of microspheres and a hardener in a solvent system. The hardener, otherwise known as an accelerator, can be, for example, ammonia, hydrochloric acid, acetic acid, ammonium carbonate, triethanolamine, calcium hydroxide, magnesium oxide, dicyclohexylamine, ammonium acetate, tributyltin, or any combination thereof The solvent system preferably comprises a water-miscible organic solvent (e.g., isopropanol, methanol, ethanol, butanol, or any combination thereof). Optionally, the solvent system also includes water.
In a preferred embodiment, the solid oxide precursor is tetraethoxysilane, the organic solvent is propan-2-ol, the hardener is ammonia, and water is present. tsp I, *
Where the intention is to optimise the coating of a surface, conditions where deposition of the newly formed solid oxide coating onto the microsphere surface is preferred over the alternative, which is the formation of a separate fraction of amorphous solid oxide. It has been found that the quality of the coating, defined in terms of percentage surface area 4, covering and thickness of deposited layer can be optimised by the choice of reaction conditions. For example:- When the hardener is ammonia, the ammonia concentration may be in the range from 3.5 to 5.5 mol per litre of reactant mixture. Preferably, the ammonia concentration is not less than 3 mol per litre of reactant mixture The water concentration may be in the range from 10 to 14 mol per litre of reactant mixture. Preferably, the water concentration is not less than 8 mol per litre of reactant mixture.
40/65096GB2 12 The concentration of microspheres may he in the range from 20 to 500 grams per litre of reactant mixture.
Preferably the precipitation reaction is carried out at a temperature in the range from 30 to 50 C. It is also preferred that the reactant mixture is stirred at a rate that keeps the microspheres well dispersed. The precursor may be added continuously. Alternatively it can be added hatchwise for example at 10 - 60 minute intervals). Typically, the precursor (e.g. TEOS) is added to the reaction mixture in from 0.84 - 450 mg per g of microsphere in order to achieve a coating of 0.2-1 OOnm solid oxide, and from 450mg - 90g per g of microsphere in order to achieve a solid oxide coating of from 0.1 to 10gm solid oxide coating.
The exact conditions of the reaction, as elaborated in the Examples, have the advantage that they permit the coating process to proceed rapidly, with almost complete incorporation (> 99%) of the solid oxide onto the surface layer, and no significant 20 formation of unwanted amorphous silica. S * . . * **
It has been found that the ability to provide a continuous layer of solid oxide that, for example, can act as a barrier to leaching of the functional layer by an acid, can be optimised by a final curing step in the process of making microspheres. Thus, preferably the method according to the second aspect of the present invention includes a curing step.
A curing step would involve ageing the solid oxide coated microspheres after the (at this stage, hydrous) solid oxide coating has been added for a period of time with the application of heat. The curing step may takes place over 2 to 24 hours, preferably more than 6, 8, 10 or 12 hours, and most preferably about 15 hours. The curing step may be carried out at a temperature of 40 - 800 C, preferably at a temperature of over 60 C, 80 C, 100 C and most preferably at from 120 C to 150 C. This curing step may be carried out under vacuum. Additionally, a wash step may follow the curing step.
As mentioned above, it has been found that the total surface area coated by the solid oxide and the ability for the solid oxide coating to retain layers of material that are 40/65096GB2 13 trapped between the solid oxide coating and the core may be optimised by the provision of a priming layer.
Accordingly, in one embodiment of the present invention the method further comprises the step of applying a priming layer to the microsphere as an intermediate step between the steps of depositing a functional layer and coating with a solid oxide. It is known how to coat particle surfaces with functional agents such as proteins. For example, Harrison et a! (J. Coil. Interface Sci 2 17 203-207 [1 999])disciose a method for coating iron particles with gelatine by refluxing the particles for 2h in an aqueous gelatine solution. However it has been surprisingly found that such extreme conditions are not in general necessary, and that good coating of, for example glass microspheres, can be obtained simply by stirring them in 1% aqueous gelatine at room temperature for 1 hour. Furthermore, by precisely controlling the ratio of gelatine (by mass) to particles (by total surface area), the amount of loosely bound (as opposed to very tightly bound) gelatin can be minimised, and thus, straightforwardly removed by a facile washing procedure. In the case of hollow * : . 20 microspheres, for example, with a median diameter of 27 p.m, gelatin binding as a function of added gelatin concentration follows a standard rectangular-hyperbolic :* : :* saturation curve, with optimum ratio of 1.2 mg gelatine per g microspheres.
As mentioned above, due to the nature of substances that are used to make a functional layer, functional layers are not usually able to chemically bind to materials conventionally used for making microsphere cores. It has, however, been found that chemically modifying the surface of the core allows the functional layer to chemically bind to the core produces a more robust attachment.
Thus, according to an embodiment of the present invention, the method further comprises the step of chemically modifying the surface of a core prior to the step of depositing the functional layer onto the core.
The chemical modification may comprise the step of anchoring a functionallayer binding agent to the core. Depending on the material used to makethe core and the choice of 40/65096GB2 14 functional-layer binding agent, the functional-layer binding agent may be able to bind directly to the core. However, the functional-layer binding agent may need to be bound to the core by a coupling agent. Therefore, in a preferred embodiment of the present invention, the step of anchoring of the functional-layer binding agent comprises the step of binding a coupling agent to the core. The step of anchoring the functional-layer binding agent may comprise the step of binding the functional-layer binding agent to the coupling agent. The coupling agent may be bound to the core prior to being bound to the functional-layer binding agent. Alternatively, the coupling agent may be bound to the functional-layer binding agent prior to being bound to the core.
The functional agent may bind directly to the functional-layer binding agent.
Alternatively, the functional agent can be coupled to the functionallayer binding agent by a coupling agent. Thus, in a further embodiment of the present application, the step of anchoring the functional agent to the core further comprises the step of coupling the functional agent to the functional-layer binding agent by a coupling agent. The coupling : . : : :* 20 agent may be bound to the functional agent prior to being bound to the functional-layer *s..
binding agent. Alternatively, the coupling agent may be bound to the functional-layer binding agent prior to being bound to the functional agent. S..
The structure of the microsphere may be strengthened further by coupling the functional :*. 25 layer to the priming layer by a coupling agent. In this embodiment, the coupling agent * :* * may be bound first to the functional layer or priming layer.
The methods of the present invention may have as their final step the coating of the solid oxide. However, the methods of the present invention may also comprise further steps in order to add layers that are external to the solid oxide coating.
Thus, in one embodiment of the present invention the method comprises the step of anchoring an effector agent to the solid oxide coating. This step may be carried out after the step of coating the microsphere with the solid oxide. The step of anchoring the effector agent may comprise the step of coupling the effector agent to the oxide coating 40/65096GB2 15 by a coupling agent. The coupling agent may be bound first to the solid oxide coating or first to the effector agent.
The above described methods allow for total control at each step in the manufacturing process as it relies upon the stepwise and sequential construction upon the surface of the microsphere. The stepwise nature of the construction permits quantitative assessment ol the quality of each layer by an appropriate chemical analysis (e.g. protein content; aminecontent; iron content) and / or physical analysis (e.g. magnetic moment) following each completed step.
In a preferred embodiment of both aspects of the present invention described above the core may be made of any material or combination of materials used in the manufacture of conventional microspheres that are used in the aforementioned procedures (e.g. separation protocols). The core may be made of an inorganic material. Preferably, the core comprises or consists of any of the following: a synthetic polymer, a natural : * : 20 polymer, a co-polymer, a block co-polymer, polymethylmethacrylic acid, a protein, a * glass, a ceramic, a ceramic oxide, or any combination thereof. When the core is made of a co-polymer, the co-polymer may comprise polymethylmethacrylic acid. In one * embodiment, the core is a borosilicate glass microsphere. The core may be buoyant, and Is.
* preferably hollow. Preferably, the core does not comprise or consist of a magnetizable agent. Porous cores are not preferred as these honeycomb" like structures may permit a * : * solvent to access the internal cavity of the core. What is preferred is a core that comprises an outer shell defining an internal void when the internal void is filled with a gas that is retained within the outer shell. The internal void may have a pressure that is less than one atmosphere.
The applicant has found that not only are buoyant microspheres most useful as the solid phase and separation technologies (as they float to the top of a liquid medium along with a bound ligand, thereby permitting easy extraction from the surface of the liquid using a magnet that is passed over the surface). The methods of constructing the microsphere according to the present invention are far simpler and cheaper to carry out when the 40/65096GB2 16 microsphere is a buoyant microsphere. Buoyant microspheres can very easily be retrieved from each step of the step-wise methods described above and are introduced to the next step of the method when buoyant microspheres are used. It is surprising that, given the density of magnetizable agents, microspheres can be produced that are both capable of being removed from a liquid surface by a reasonably sized magnet and of also being buoyant.
For the avoidance of doubt, a buoyant microsphere is one that is less dense than, or in some cases isodense with, the liquid medium in which it is being suspended. Buoyant microspheres float to the surface of the liquid medium in which they are suspended.
IS Isodense microspheres may be suspended in a liquid medium. The skilled person would understand that, by virtue of the conditions of the manufacturing process, smaller particles tend to have higher buoyant densities than do larger. For example, microspheres with a medium diameter of 27 micrometers and a final density of approximately 0.5 g/cm3. On the other hand, a smaller base microsphere (diameter 18 micrometers) is much :.:::. 20 denser, and the final coating microsphere has a density of 0.6 g/cm3. Smaller * microspheres have the advantage, v/dc' supere, that fewer need be added to a sample to provide any given total surface area. Exact choice of size and density of a specific application is one which is made on a case-by- case basis. Not wishing to restrict it S..
further, but in the interest of clarity, it has been found that the preferred microsphere of the present invention of a buoyant density of less than 0.9 g/cm3, preferably from 0.05 to 0.85, from 0.2 to 0.8, from 0.3 to 0.7 g/cm3. The buoyant density of the microsphere may be 0.6 g/cm3. The microsphere may be hollow. Final coated microspheres may be hydrophilic and therefore mix well with water and other polar liquids and liquid mixtures.
The microspheres may be stable in solvents over a wide range of temperatures and pH conditions.
A preferred core for the current invention is a hollow silica microsphere. Such microspheres, which are commercially available, will be more than I tm in diameter. As the core forms the greater part of the microspheres of the present invention, it will also have a diameter of greater than I m. The applicant has found that it is important to use 40/65096G32 17 microspheres and cores of such dimensions. Smaller cores, for example, are disproportionately small compared to ligands one may wish to bind the microsphere too, or present too small a surface area to be useful for paints. In a further preferred embodiment the core has a diameter that is less than 1000, 500, 100, 50, or 10 jim. The diameter of the core is preferably greater than I, 5, 10 or 15, jim, and most preferably 5 jim, in diameter. The core is preferably roughly spherical.
In a preferred embodiment of both aspects of the invention described above the coupling agent is any agent that is capable of binding an inorganic molecule to an organic molecule. More specifically, the coupling agent may be any agent that is capable of binding a glass, iron oxide, spinel ferrite to an organic molecule. The coupling agent may be a silane, a germane, or a combination thereof. The silane may be any of the following; an amino silane, a carbonyl silane, a carboxy silane, a hydroxyphenyl silane, a sulthydryl silane, 3-aminopropyltrimethoxysi lane, or any combination thereof.
*:: . 20 In a further preferred embodiment of both aspects of the invention described above the ** functional-layer binding agent comprises or consists of any of the following; a synthetic * polymer, polymethylmethacrylic acid, a co-polymer, a block co-polymer, a natural * :1* polymer, a protein, a peptide, an amino acid, or any combination thereof. Essentially, the : functional-layer binding agent is preferably an agent, that includes an active group such as -Nl-17, -C=O, -COOH, -OH, or any combination thereof. Preferably, the functional- layer binding agent is a protein such as a serum albumin (e.g. bovine serum albumin, human serum albumin, chick serum albumin) or gelatine, or collagen. Alternatively a man-made polymer, such as polyvinylalcohol, may be used.
The skilled person would understand that any agent that could confer a useful function on a microsphere once that agent is coated on the microsphere would be useful for incorporating into the functional layer of the present invention. Although a number of specific examples have been provided (e.g. magnetizable agents, coloured agents, fluorescent agents, radioactive agents, fire-retardents) it should be understood by the above discussion that the invention could be realised using a wide array of functional 40/65096GB2 18 layers that would be known to the person skilled in the art and so should not be limited to any one of the specific examples provided.
In a preferred embodiment of both aspects of the invention described above the functional layer may comprise or consist of any agent that is capable of being manipulated by a magnetic field, and so is made of a magnetizable agent. Preferably, the magnetizable agents exhibit magnetic behaviour only whilst being exposed to a magnetic field, and are not permanent magnets. Thus, the microspheres do not aggregate together when a magnetic field is not present. Induced permanent magnetism following the application and then removal of an externally applied magnetic field to microspheres in suspension (e.g. in a liquid sample) may lead to a magnetic agglomeration of the microspheres. This is undesirable in a diagnostic environment where a thoroughly dispersed solid phase offering high surface area is essential for rapid and efficient (quantitative) binding of the analyte. Preferably, therefore, these agents are superparamagnetic, rather than simply paramagnetic for avoidance of doubt a * 20 superparamagnetic agent is one that becomes strongly magnetized in the presence of the IS.* . . . . magnetic field, but loses that induced magnetism entirely when the applied field is * withdrawn. By contrast a paramagnetic agent is one that is likely to retain a degree of residual magnetism after the magnetic field is withdrawn.
* 25 When an agent is paramagnetic or superparamagnetic chiefly depends on the size of the individual particles, where smaller particles that is, those most closely constituting a single magnetic domain, will be superparamagnetic and larger particles (constituting an assembly of many magnetic domains) will be paramagnetic. Typically, a superparamagnetic particle, that is constituting a single magnetic domain, will have a diameter of less than 100 nm, and typically 10 - 30 nm. The magnetite (magnetic iron oxide particles used in Example 8 have a median diameter of 30 rim, for example.
The magnetizable agents may comprise any of the following; a paramagnetic agent, a superparamagnetic agent, iron, nickel, iron oxide, a spinel ferrite, an alloy, or any combination thereof. For the avoidance of doubt, a spinal ferrite can have the generic 40/65096GB2 19 formula MFe2O4, where M is a metallic element including, but not limited to, any of Co, Mg, Mn and Zn, or any combination thereof It is preferred that magnetizable agents are in the form of nanoparticles. Accordingly, the magnetizable agents preferably have a diameter of less than 300nm, 200nm, lOOnm, 5Onm or 3Onm. Magnetizable agents may have a diameter from 10 to 100, from 15 to 70, or from 20 to SOnm.
Preferably the magnetizable agent coated microspheres have magnetic moments that are sufficiently high that the application of a magnet is sufficient to remove the microspheres from the surface of an aqueous sample, or to draw them quantitatively from suspensions to the side of sample tube under conditions of agitation.
It has surprisingly been found that preparing the magnetizable agents using a high-shear mixing process, preferably wherein the magnetizable agent is mixed in an aqueous :,:*.. 20 medium in a high-shear mixing machine, is particularly preferred. Magnetizable agents prepared in this way exhibit a higher level of retention on the final constructed microsphere than other forms of magnetizable agents, e.g. magnetizable agents formed by sonication. The applicant has found that mixing high-shear magnetite with bovine serum a..
albumen (BSA)-coated microspheres (prepared, for example, in accordance with the example 8) yields dark, highly magnetizable and superparamagnetic particles, indicative of a high retention of magnetite particles on the surface. On the other hand, magnetite pre-treated by sonication gives a very sparsely coated, and therefore weakly magnetizable microsphere, indicative of a low retention of magnetite in the final particle. Therefore, in a preferred embodiment of the first aspect of the present invention, the magnetizable agent is a high-sheared magnetite. In a preferred embodiment in the second aspect of the present invention the method includes a pre-treatment step for the magnetizable agent, prior to introducing the magnetizable agent to the microspheres, that it includes the high- shear mixing of the magnetizable agent. An alternative manner of producing a magnetizable agent that has also been found to he superior to sonication is by 40/65096GB2 20 precipitation from an ammoniacal Fe(11)/Fe(111)solution. Thus, the pre-treatment step may instead include the aforementioned precipitation step.
The steps of binding the magnetizable agent to the microsphere preferably do not involve the application of heat (i.e. by a furnacing step).
Alternatively, the functional layer may comprise or consist of one or more coloured or fluorescent agents. Such agents may be conventional coloured or fluorescent agents (for example, pigments, paints, inks, preferably with a low molecular-weight i.e. 1000 amu or less), polymeric organic pigments, including lakes, inorganic substances such as transition metal salts, such as chromium dioxide or ammonium polyphosphate, organometallic substances such as a zinc porphyrin, or any combination thereof.
Alternatively, the functional layer comprises or consists of one or more radioactive agent.
The radioactive agents may be made from any radioactive substance that is suitable for :.:::. 20 killing cells. For example, the radioactive agent may comprise iodine-125, iodine-l31, palladium, radium, iridium, or cesium. * **
* It is preferred that the functional layer comprises functional agents that are in the form of S..
nanoparticles. Accordingly, the functional agents used to make the functional layer * . * 25 preferably have a diameter of less than 300nm, 200nm, lOOnm, SOnm or lOnm. The functional agents may have a diameter from 10 to 100, from 15 to 70, or from 20 to 50 nm. It is also preferred that the formation of the layer using nanoparticles produces a rough textured surface on the microsphere. As has been discussed above, the rough textured surface may increase the surface area of the mierosphere and so can optimise the deposition and retention of any further layers on the microsphere. The functional agents are preferably roughly spherical.
In a preferred embodiment of both aspects of the present invention the priming layer may comprise or consist of any of the following; a synthetic polymer, polymethylmethacrylic acid, a co-polymer, a block co- polymer, a natural polymer, a protein, a peptide, an amino 40/65096GB2 21 acid, or any combination thereof. Essentially, the priming layer should be an agent that includes an active group such as -NH2, -C=O, -COOl-I, -OH, or any combination thereof.
Preferably, the functional-layer binding agent is a serum albumin (e.g. bovine serum albumin, human serum albumin, chick serum albumin) or gelatine.
For the avoidance of doubt, the term "solid", as used in the term "solid oxide", should be understood to mean that the oxide is in a solid state at the temperature and pressure at which the microspheres are used. Preferably, the microspheres are used at Standard Ambient Temperature and Pressure, and so the oxide coating would be solid at 25 C and at a pressure of lOOkPa. In a preferred embodiment of both aspects of the present invention the solid oxide is an amorphous glass or ceramic coating. The skilled person would understand which oxides are capable of forming amorphous glass or ceramic coatings. However, in the interests of clarity, but not wishing to be restricted further, the solid oxide may be any of the following: silica, titania, zirconia, alumina, magnesia, or any combination thereof In a preferred embodiment, the coating is polymeric silicon : 20 dioxide (silica) and silica particles and coatings are conveniently generated by the hydrolysis of an alkoxysilane such as tetraethoxysilane. * S.
The solid oxide laid down in the above methods and coated on the above microspheres preferably forms a substantially continuous coating over the surface of the microsphere.
The solid oxide may coat from, 70-100, 80-100, 90-100, 95-100, or 100% of the surface * .* area of the microspheres, preferably 100%. The percentage coating of a microsphere may be determined by, for example, microscopy..
It has been surprisingly found that it is possible to apply substantially continuous coating of the solid oxide over the surface of the microsphere according to the present invention such that external environmental forces cannot interact with the enclosed functional layer.
For example, the silica coated protects the underlying functional layer from acid-attack, as described in example 9 below.
40/65096G32 22 in a further preferred embodiment of both aspects of the present invention described above the effector agent is an affinity binding agent. Affinity binding agents have a binding affinity for a selected target, e.g. an analyte, for example a specific molecule or cell. Accordingly, the effector agent can be one partner of any binding partnership known to the skilled person, where the other partner is associated with or is the target. Not wishing to he limited lurther, but in the interests of clarity, the effector agent may comprise any of the following; a protein, an antibody, a lectin, an enzyme, a polypeptide, a nucleotide, a polynucleotide, a polysaccharide, a metal-ion sequestering agent, biotin, avidin, or any combination thereof.
It has been found that the microspheres according to the first aspect of the present invention, and the microspheres prepared according to the method of the second aspect of the present invention can include a surprisingly large amount of functional layer, and effector agent when compared to the amounts that would have been possible if the microspheres were constructed in accordance with prior art methods. * ** * 20 I...
Thus, in a further preferred embodiment of both aspects of the invention described above the microspheres comprise no less than 0.1, 1,2,3,4,5,6, or 7mg of protein per gram of * microsphere. Preferably, the microspheres comprise from 0.1 to 30, from 6 to 24, from 10 to 20, or from 12 to 24mg protein per gram of microsphere. Following binding of the * :. 25 functional-layer binding agent to the microsphere, but prior to binding the functional layer, the microsphere preferably comprises at least 0.5, 1,2,3,4mg of protein per gram of microsphere, more preferably from 4 to 15, from 4 to 10, from 4 to 7 mg protein per gram of microsphere.
Although not wishing to be bound by theory, it is suggested that the ability for the microspheres to incorporate such large amounts of protein is as a result of the robust nature of the construction of the microspheres. Any layer" of construction of the microspheres is preferably bound to the next by a chemical bond. The chemical bond is preferably a covalent bond, an electrostatic bond, hydrophobic interaction, or any combination thereof.
40/65096GE2 23 in a preferred embodiment of both aspects of the invention described above the microsphere may comprise at least 10, 20, 40, 80, 100 mg of magnetizable agent per gram of microsphere, more preferably from 100 to 500, from 150 to 400, or from 200 to 300 mg of magnetizable agent per gram of microsphere.
In a preferred embodiment of both aspects of the invention described above the microsphere is a buoyant microsphere. The microsphere may have a buoyant density from 0.05 to 0.99, from 0.2 to 0.8, from 0.3 to 0.7 g/cm3. The buoyant density of the microsphere may he 0.6 g/cm3. The buoyant density of the core may be 0.3 g/cm3. The final microspheres may be hydrophilic and therefore mix well with water and other polar liquids and liquid mixtures. They may be stable indefinitely in such solvents over a wide range of temperature and pH conditions.
In a further aspect of the present invention, there is provided a composition for use as a paint comprising any of the aforementioned microspheres and one or more binder. The binder may be any binder known in the art and preferably one that is capable of acting as a vehicle for the microspheres and eventually solidifies to form the dried paint film.
Examples of suitable binders are synthetic or natural resins such as acrylics, polyurethanes, polyesters, melamines, oils, latex, or any combination thereof. The composition may also comprise a diluent and/or an additive. The diluent is used in order to adjust the viscosity of the paint and may, for example, include water or an organic solvent (such as alcohols, ketones, esters, glycol ethers, or any combination thereof).
Additives may include pigments or colouring agents, catalysts, thickeners, stabilizers, em u I sifiers, texturizers, adhesion promoters, flatteners, or any combination thereof.
In further aspect of the present invention, there is provided a microsphere prepared according to any of the above described methods.
In a further aspect of the present invention, there is provided a microsphere according to the first aspect of the present invention that is prepared according to the methods of the 40/65096GB2 24 second aspect of the present invention.
As discussed above, it can he expected that the microspheres according to the present invention that comprise a radioactive functional layer are able to be used in a method of treatment, e.g. treating cancer.
Thus, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising the microspheres according to the first aspect of the present invention. Particularly, those microspheres that include a functional layer that comprises or consists of a radioactive agent and an effector agent. The effector agent preferably targets a specific cell type, most preferably a cancer cell and is an antibody. The pharmaceutical composition may further comprise any pharmaceutically acceptable excipients, binders, fillers, stabilizers, or any combination thereof.
In a further aspect of the present invention there is provided a method for treating a proliferative disorder (such as cancer), by administering a composition comprising an effective amount of a microsphere according the first aspect of the present invention to a subject suffering from a proliferative disorder. Preferably, microspheres are those that : include a functional layer that comprises or consists of a radioactive agent and an effector agent. The effector agent preferably targets a specific cell type, most preferably a cancer * 25 cell and is an antibody. The composition may comprise any pharmaceutically acceptable excipients, binders, fillers, stabilizers, or any combination thereof.
In a further aspect of the present invention, there is provided a composition comprising a microsphere according to the first aspect of the present invention for use in a method of treatment. Preferably the method of treatment is for treating a proliferative disorder (such as cancer). The microspheres are preferably those that include a functional layer that comprises or consists of a radioactive agent and an effector agent. The effector agent preferably targets a specific cell type, most preferably a cancer cell and is an antibody.
The composition may comprise any pharmaceutically acceptable excipients, binders, fillers, stabilizers, or any combination thereof 40/65096G32 25 In the most preferred embodiment of the first aspect of the present invention, there is provided a buoyant microsphere that comprises a core, a functional layer and a solid oxide, wherein the functional layer forms an intermediate layer between the core and the solid oxide coating and the solid oxide coating forms a substantially continuous coating of form 0.2 to 100, preferably from 0.2 to 50 nm thick. The most preferred embodiment of the second aspect of the present invention is a method of making the aforementioned buoyant microsphere.
It should be understood that the microspheres described in the first aspect of the present invention, and those produced by the method according to the second aspect of the present invention are used in large numbers. Accordingly in a further aspect of the present invention there is provided a multitude of microspheres consisting of or comprising a population of the microspheres described above.
In a further aspect of the present invention, there is provided a method substantially as herein described. I *
In a further aspect of the present invention, there is provided a microsphere substantially * as herein described and shown in the figures. I I *
In yet a further aspect of the present invention there is provided a composition substantially as herein described.
An example of the microspheres and methods according to the present invention will now be described, by way of example only, and will make reference to the following drawings.
Figure 1 shows a microscope photograph of a nickel coated microsphere prior to app'ying a silica coating.
40/65096GB2 26 Figure 2 shows a microscope photograph of a nickel coated microspheres with an outer coating of silica.
Figure 3 shows a microscope photograph of a nickel coated microsphere with an outer coating of silica.
Figure 4 shows microscope photograph of a nickel coated microsphere with an outer coating of silica, after the nickel has been removed by treatment with hydrochloric acid.
Magnification x 400. The core microsphere (diameter 50 tm is coated with a silica layer of uniform thickness 1 7 m, approximately. A is the hollow microsphere core, B is a space left by the removal of the nickel layer, C is the deposited silica layer.
Example I
Coating of a sample of Nickel-coated glass microspheres with a layer of gelatine a * * S * I... S..
Glass microspheres are commercially available from a number of manufacturers. This Example utilizes a hollow gas-filled borosilicate glass microsphere (Eccosphere brand; Emerson and Cuming, Billerica, MA) Eccospheres are available in different size grades and the procedures below refer specifically to the grade SI-200, which are smooth, :.. perfectly spherical microspheres with a mean diameter of 55 micrometers. The * * , 25 procedures below refer to a batch of said microspheres that were nickel-coated by chemical vapour deposition process, by Powdermet mc, Euclid OH.). The resultant material contained 52% wt nickel, a mean true particle density of 0.634g1cc and a mean diameter of 57 micrometers.
II.6 grams of a 45% w/v solution of cold-water fish gelatin solution (Sigma (RTM) Aldrich cat. no. G7765), was diluted with 520 ml deionized water (final gelatin concentration, 1% w/v). 5g of microspheres were added and the mixture warmed to 90 C on a hot-plate, with occasional stirring,for 90 mm. The suspension was poured into a No. 40/65096G32 27 2 glass sinter funnel attached to a Buchner flask, to which had been added 50 ml de- ionized water, with stirring. The water was removed under vacuum and 150 ml de- ionized water added to the funnel. The microspheres were re-dispersed by gentle stirring and the water removed under vacuum. This procedure was repeated with de-ionized water a further four times. The microspheres were finally split into four equal batches and each was suspended in 50 ml de-ionized water. They were centrifuged at 2500 rpm for 5 mm. The surface pellet was gently stirred to re-disperse, without disturbing the pellet, and centrifuged again. This procedure was repeated twice more.
The buoyant microsphere fraction was transferred, using a magnetic pickup, to a 1 Litre beaker containing 450 ml de-ionized water. The beaker placed on a ring magnet, with gentle stirring to facilitate the settling of the highly magnetizable microsphere fraction.
The supernatant, including a fraction of weakly magnetizable material, was decanted off and the settled material was re-suspended in a further 450 ml de-ionized water and the above procedure was repeated a further three times. The recovered microspheres were * : . * 20 transferred to a No. 2 sintered glass funnel attached to a Buchner flask, to which had been I...
added 50 ml methanol, with stirring. The methanol was removed under vacuum and 20 * * ml methanol was added to the funnel. The microspheres were redispersed by gentle : stirring and the methanol removed under vacuum. This procedure was repeated a further four times with 20 ml methanol and then five times with 20 ml diethyl ether. The recovered microspheres (2.75 g) were cured overnight at 120 C under vacuum to yield a * :* : dark-grey free-flowing powder.
Figure 1 clearly shows the layer of nickel surrounding the core. As is demonstrated by this figure, the nickel layer provides the surface of the microsphere with a particularly rough textured surface.
Example 2
Gelatin assay of microspheres 40/65096GE2 28 This procedure enables the gelatin content of microspheres to be measured using a modification of the bicinchoninic acid (BCA) method (Pierce Chemical Co. Rockford, 11).
The procedure was carried out as follows: Assay standards were first of all prepared using gelatin from cold water fish skin (45% w/v in water; Sigma (RTM) product # G7765). A working stock was prepared at 2000jig/ml and diluted in triplicate to 0, 25, 125, 250, 500, 750, 1000, 1500 & 2000tgIm1 by dilution with deionized water. 50 p.1 of each standard was transferred to 1.5 ml Eppendorf tubes.
In triplicate, between 8 and 10 mg of gelatin-coated glass microspheres were weighed into I.5 ml microfuge tubes.
The BCA assay working reagent was prepared by mixing reagents A and B (standard reagents presented in the bicinchoninic acid (BCA) tests of Pierce Chemical Co. Rockford, II as A and B) in the ratio 50:1, then vortexed to mix. 1.0 ml of working * : : :* reagent was added to each of the standard tubes and to each of the microsphere sample tubes. The tubes were capped and vortexed, and then incubated at 37 C for 30 minutes.
At 10 minute intervals throughout the incubation period, the tubes were removed from the incubator and inverted several times to mix.
At the end of the incubation period, the tubes were inverted for a final time. The tubes containing microspheres were then placed against a magnet, so clearing the solution, and the solutions transferred to I ml disposable spectrophotometer cuvettes. The standard solutions were transferred directly to cuvettes.
The Absorbance of each cuvette was read at 526 nm, without delay, using the 0 p.g/ml standard as a blank. The Absorhance reading of the sample solutions was converted to a mass of protein (in mg) from the derived standard curve, and then divided by the 40/65096GB2 29 recorded mass of microspheres (in grams) for that sample, to give the gelatin content in mg per gram microspheres.
The gelatin-content of the microspheres prepared in Example 2 was found by this method to be 7.8 mg I gram microspheres.
Example 3
Silica-coating of microspheres.
The following procedure may be used to coat microspheres that have or have not been I 5 prior-treated by coating with gelatin 0.8g gelatin-coated microspheres prepared in Example 1 were stirred at 300 rpm with a mixture of 30m1 isopropanol and 12.6m1 concentrated aqueous ammonia (density 0.9glcc), in a 250 ml three-necked round bottomed flask at 40 C. 8 x 0. 171 ml (0.767 IS..
s.. 20 mmol) of tetraethoxysilane [78-10-4] were added at 45 mm. intervals by means of a graduated pipette. Each cycle of tetraethoxysilane generates a deposited silica layer of approximately 1.7 m, so that the total layer thickness after eight additions is approximately 14 tm. After the final addition the reaction mixture was stirred for an :.. additional 45 mm. and then poured with stirring into methanol (100 ml) which was in a * :* 25 N 2 sintered glass funnel attached to a Buchner flask, and the methanol removed under vacuum. The vacuum was turned off, 30 ml methanol was added with brief stirring to disperse the product, and the methanol removed under vacuum. This procedure was repeated five times in total with methanol and five times with diethyl ether. The microspheres were cured in a vacuum oven at 120 C overnight to yield a light grey free flowing powder (1.1 g). This material was suspended in 50 ml de-ionised water and centrifuged at 100 x g for 3 mm. The surface plug was stirred gently to re-disperse, without disturbing the bottom pellet, and centrifuged again. The buoyant material was transferred with a magnetic pen to a new 50 ml centrifuge tube and 35 ml de-ionised water added and the tube was vortexed for I mm. 15 ml of de-ionised water added then 40/65096GB2 30 centrifuged at 100 x g for 3 mm. This process was repeated three times. The buoyant material was transferred with a magnetic pen to a new 50 ml centrifuge tube and 35 ml 0.IM hydrochloric acid added and the tube was vortexed for I mm. 15 ml of de-ionised water added then centrifuged at 100 x g for 3 mm. This process was repeated three times.
The buoyant material was transferred with a magnetic pen to a new 50 ml centrifuge tube and 35 ml de-ionised water added and the tube was vortexed for I mm. 15 ml of de- ionised water added then centrifuged at 100 x g for 3 mm. This process was repeated three times. The pH of the supernatant liquid was 7. The buoyant material was transferred into methanol (50 ml) which was in a N 2 sintered glass funnel attached to a Buchner flask, and the methanol removed under vacuum. The vacuum was turned off, 30 ml methanol was added with brief stirring to disperse the product, and the methanol removed under vacuum. This procedure was repeated three times in total with methanol and three times with diethyl ether. The microspheres were cured in a vacuum oven at 120 C for 30 mm. to yield a light grey free flowing powder (0.51 g). Under the microscope an apparently continuous covering of silica is clearly visible, as shown in . 20 Figure 3. S..
* * : :. The apparent gelatin content of the silica-coated microspheres was measured using the BCA assay as described in example 2. Compared with non-treated microspheres (scoring 100% in the BCA assay), the silica-coated microspheres scored only 5%. This result is : 25 consistent with a silica surface-covering of at least 95%, on the assumption that silica- . .: coated gelatin is not accessible to the BCA reagent.
The silica coated microspheres produced by this method are shown in Figure 2.
Example 4
Amino-functionalization of silica-coated microspheres 40/65096G32 31 0.25g of microspheres prepared in Example 2 were suspended in 2.5 ml 95% aqueous MeOH in a screw-cap 50 ml polypropylene centrifuge tube and placed in an ultrasound bath for 30 seconds to disperse thoroughly. 0.048 g 3-aminopropyltrimethoxysilane was added and placed on a blood-tube wheel for 30mm. The suspension was then poured into a No.2 sintered glass funnel attached to Buchner flask and the solvent removed under vacuum. The vacuum was turned off and 20 ml methanol was added to the funnel with gentle stirring to re-disperse the microspheres. The vacuum was turned on to remove the methanol. This procedure was repeated a further three times with methanol, then three times with diethylether. The funnel was then placed in a vacuum oven at 120 C for 1 hour. 0.1 85g microspheres were recovered as a light-grey free-flowing powder.
Using the procedure described in Example 5, the amino-group content of the microspheres was found to be 15.7 tmol -NH2/g.
:::. Example5
* 20 Determination of the amino-group content of microspheres * *** This assay takes advantage of the colorigenic reaction of ninhydrin with primary amines and the present procedure is modified after Sarin et al. (1981) Anal. Biochern. 11 7:147. * S
Two reagents are required as follows: Reagent A: 6.5 mg potassium cyanide was * dissolved in 100 ml dc-ionized water and I ml of this was diluted with 49 ml pyridine. 8 g of phenol was dissolved in 2 ml of ethanol (with warming), and the two solutions were mixed together. Reagent B: 500 mg ninhydrin was dissolved in 10 ml of ethanol.
The procedure was carried out as follows: In triplicate, between 8 and 10 mg of amino- functionalized microspheres, as prepared in Example 3, were weighed into a 1.5 ml Eppendorf tube. Triplicate no-microspheres control tubes were included as blanks.
40/65096GB2 32 180 tl of' reagent A was added to each tube, followed by 40.il of reagent B. The tubes were vortexed for two seconds and then placed in a heating block pre-heated to 70 C.
For 3 successive 5 minute intervals each tube was removed in turn from the heating block, vortexed for two seconds, and then placed hack in the block. Five minutes after the last round of vortexing the tubes were removed from the block, vortexed for two seconds and then placed on ice for 5 minutes. The tubes were then placed against a magnet, so pulling the microspheres to the side, and 100 l of the solution was withdrawn to a clean microcentrifuge tube containing 900 tl of 60% v/v ethanol in water. The tubes were capped and vortexed for 5 seconds to mix. The samples were finally transferred to disposable plastic micro-cuvettes. A spectrophotometer set at 570 nm was set to zero with the blank sample then the absorbance of each sample is recorded. The amine content of the microspheres (in.tmol NH2/g microspheres) was calculated from (A570 x 147) / (exact mass of microspheres, in mg), and the mean of the triplicate estimates is stated.
Example 6
* . 20 Removal of nickel from silica-coated nickel microspheres **** * ** Removal of the nickel layer from silica coated microspheres permits the exact thickness of the new silica layer to be measured by light microscopy, since the * * * interface between the inner (core) and deposited outer layer is clearly seen.
Nickel-coated microspheres without a silica coating (0.5 g) were placed in 37% hydrochloric acid (10 ml) with gentle stirring. Hydrogen bubbles formed rapidly on the surface of the microspheres and the supernatant liquid turned green due to formation of Ni. The microspheres turned white as the reaction proceed to completion, in less than I hour. By contrast, when nickel microspheres coated with silica, as prepared in Example 3, were treated with 37% hydrochloric acid, development of the green colour proceeded much more slowly, and was not discernable until ca. 30 mm; hydrogen bubbles did not appear, and the nickel was not completely removed (microspheres completely white) until 5-6 hours had elapsed.
40/65096G32 33 The relative resistance of the nickel layer to acid treatment is consistent with protection of the nickel layer by the silica layer.
Microspheres from which the nickel has been completely removed are transparent and the interface between the original microsphere and the deposited silica layer, which is approximately 1 5 tm in thickness, is clearly visible (Figure 4).
Example 7
Coating of silica-coated nickel-coated microspheres with antiCryplosporidium antibody In this procedure antibody is coupled to the microsphere surface by random glutaraldehyde cross-linking between surface- and protein-amino groups.
(a) antibody derivatization. A number of anti-Crvpiosporidium oocystspecific antibodies * : 20 are commercially available. This example utilizes the mouse monoclonal antibody 2C9, available from Waterborne Inc. (New Orleans, LA), which was purified from ascites fluid, as per the manufacturer's instructions, before use. The protein concentration was determined by measuring the absorbance at 280 nm (antibody concentration in mg/mi = A280/l.3).
(b) Functionalization of micraspheres with antibody. 25.5 mg of silicacoated * .: microspheres prepared in Example 3 were weighed into an Eppendorf tube, followed by I ml of carbonate buffer. The microspheres were dispersed by gentle shaking and allowed to stand 5 minutes. The floating microspheres were transferred to a second Eppendorf tube containing 1 ml carbonate buffer (0. I M Na2CO3 pius 0. I M NaHCO3, pH 9.5), using a magnetic pen, followed by 500 p110% aqueous glutaraldehyde, prepared by diluting the 50% stock with carbonate buffer. The tube was attached to a blood-tube wheel, clamped vertically, and allowed to rotate for two hours at 30 rpm, room temperature. The microspheres were then washed by transferring successively to 6 x I ml carbonate buffer, with 5 mm. on the blood-tube wheel between transfers. 500 p1 of purified 2C9 antibody 40/65096G32 34 (100 tg/ml in carbonate buffer) was then added, and the tube placed on the blood-tube wheel and incubated overnight (30 rpm, room temperature). Freshly prepared aqueous sodium cyanoborohydride was then added, to final concentration of 50mM, and the tube returned to the wheel for 30 mm. Unreacted aldehyde sites were blocked by addition of aqueous ethanolamine hydrochloride solution, pH 9.5 to final concentration 50mM, and the tube returned to the wheel. The microspheres were finally washed by successive transfers into 5 x Imi of PBS-azide (10mM Phosphate, 2.7mM KCI and 137mM NaCI; pH7.4 containing 0.02% sodium azide) with 5 mm. on the wheel between transfers and stored at 4 C.
Example 8
Preparation of a magnetite coated, silica-coated microsphere for diagnostic applications * : . 20 (ii) APS coating of hollow glass microspheres S... * * * S**
* 294.46g of 27im hollow glass microspheres were treated with 59g 3trimethoxysilylpropylamine (APS) in 3000m1 95% aqueous methanol. These beads : (282.92g) are cured under vacuum at 70 C for 3 hours.
* * 25 * * (II) Assay of amino groups The microspheres prepared above were assayed using the method described in Example 5. A value of 6.3 j.imoles NH/g microspheres was obtained.
(iii) Gelatin-coating of amino functionalized microspheres 50.OOg of microspheres were boiled in an aqueous solution of 45% cold water fish gelatin (26 mg/mI) for 1 hour. The microspheres were then washed thoroughly with deionised 40/65096GE2 35 water, deionised:water:methanol (1:1) and finally methanol. The recovered microspheres (49.63g) were cured under vacuum at 120 C overnight.
(iv) Protein determination of gelatin-coated microspheres The gelatincontant of the microspheres prepared above was assayed as described in Example 2. A value of 3.6 mg gelatin/g microspheres was obtained).
(v) Magnetite-coating of microspheres Magnetite 20g was suspended in I litre deionised water and subjected to high shear mixing (7500 rpm) for 15 minutes.
The microspheres from (iii) were mixed with high shear magnetite in the ratio 1:0.75 w/w in water. The suspension was placed on an orbital shaker at room temperature for 1 hour.
* 20 The microspheres were recovered by centrifuging the mixture at 1500 x g for 15 minutes.
The floating fraction was transferred with a magnetic pen to fresh centrifuge tube containing 50 ml distilled water, shaken to disperse and then centrifuged again. This * procedure was repeated a further four times. After the last wash the microsphere were : dispersed in 30 ml methanol in a Buchner funnel (No2. sinter) attached to a Buchner * 25 flask and vacuum line. The vacuum was turned on to remove the methanol. The vacuum * :* * was turned off 30 ml methanol was added and the product resuspended by gentle stirring.
The vacuum was turned on to remove the methanol. This procedure was repeated three times with 30 ml methanol and then once with 30 ml methanol/diethylether (1:1 vlv). The vacuum was left on to air-dry. The material was dried in a vacuum at 120 C, overnight.
(vi) Assay of bound magnetite The iron content of magnetite-coated microspheres is determined by nitric acid treatment of a sample of the microspheres, which quantitatively releases the iron into solution as a 40/65096GB2 36 mixture of Iron (11) and Iron (111). The iron is quantitatively reduced to Iron (11) using hydroxylamine and titrated using 1,10-phenanthroline. The concentration of the Fe(II)- I, I 0-phenanthroline complex is determined spectrophotometrically.
Between 3 and 4 mg of magnetite-coated microspheres were weighed out in triplicate.
1 ml of 6 M nitric acid was added to each tube and vortexed to mix. The tubes were placed in a heating block at 90 C for 4 hours, with vortexing every 30 minutes. The tubes were removed from the block from and centrifuged For 30 seconds at 12 000 x g.
j.il of the solution from the middle of the reaction tube mixture (avoiding material at top and bottom of the tube) was transferred into an Eppendorf tube to which had been 175 p.l deionized water. 400 jtl of I M K2HPO4 was added to neutralize the solution, followed by 400 il of 1% hydroxylamine hydrochloride solution in water. 400.il of 0.1% 1,10-phenanthroline in 12.5mM sodium acetate was added and the tubes vortexed briefly to mix. The tubes were placed in a heating block at 80 C for 20 mm, then removed and allowed to cool. 250 il of the solution was transferred into a plastic disposable 20 spectrophotometer cuvette, followed by 750 il of de-ionized water. The absorbance at : :: * 5 10 nm was measured using water as the blank. The iron content, in mg iron per g microspheres is given by (As() x I 136)/(mass of microspheres in grams). The stated value is the mean of triplicate readings.
* :. 25 The 1,1 0-phenanthroline iron assay was used to determine the level of iron incorporation and typically a value of 230mg Fe/g microspheres was obtained.
(vii) Silica glass coating of microspheres 37 ml iso-propanol, 30 ml concentrated aqueous ammonia and I.OOg of magnetite coated microspheres prepared in (v) were placed in a I OOml round bottom flask. The was fitted with a mchenical stirrer and placed in a heating mantle se and heated to constant temperature 60 C, with stirring at 300 rpm. 307.5 tl (0.2868 g) tetra-ethoxyorthosilicate (TEOS) was added and the mixture stirred for 20 minutes. The product was recovered by vacuum filtration through a Buchner funnel (No2. sinter). The vacuum was turned off. 30 40/65096G32 37 ml methanol was added and the product resuspended by gentle stirring. The vacuum was turned on to remove the methanol. This procedure was repeated three times with 30 ml methanol and then once with 30 ml methanol/diethylether (1:1 v/v). The vacuum was left on to air-dry. The material was dried in a vacuum at 120 C, overnight.
The final product was a free-flowing powder, yield 1.07 g (theoretical yield I.08g). The weight increase corresponds to a continuous silica layer that is roughly 60 nm in thickness.
Example 9
Demonstration of acid resistance of magnetite-coated microspheres In certain immunodiagnostic procedures it may be necessary to perform a release step to separate immunocaptured analyte from the solid phase. A common way of achieving this is a very low- or very high pH wash, which has the effect of inactivating the antibody.
* One such example is the assay of water samples for oocysts of Ciyptosporidium parvurn, where the acid elution step is necessary to separate the oocysts from the microspheres prior to a microscope slide count. A procedure for the assay of Cryptosporidium oocysts using buoyant superparamagnetic microspheres was disclosed in co-pending application PCT/GB/2006/00 1896. Acid elution of the bound analytes from a bare' magnetite- * coated buoyant microsphere can lead to partial dissolution of the magnetite and hence generate artefacts, particularly during microscopic evaluations, which render the slide examination more difficult. In principal, the silica coating should prevent this, and in order to test the hypothesis, the magnetite coated, silica-coated microspheres prepared in Example 8 (v) were subjected to an acid test. In addition, microspheres coated with anticryptosporidium antibody (using the means disclosed in Example 7 above) were used in to assay for Cryptosporidium ococysts in water, as described in PCT/GB2006/OOl 896.
The acid test was carried out as follows: 10mg of the microspheres prepared in Example 8 (v) were placed in small glass tube together with I ml cone. I-IC1. A stopwatch was 40/65096GB2 38 started immediately and the time taken for the microspheres to turn white was recorded (this corresponded to the appearance of the intense yellow colour of FeCI3 in the medium). Magnetite-coated microspheres with no silica coating treated in this way become white immediately on contact with the acid solution. By contrast, the microspheres prepared above were still intact (brown, with no yellow FeC] in medium) after 10mm. The experiment was repeated with microspheres coated with a silica layer 1110th and 11100th that of these (corresponding to a continuous coat thickness of roughly 6nm, and 0.6 nm. These failed after 5 mm. and I mm, respectively.
Therefore it was concluded that thicker layers of silica confer significant protection of the magnetite layer against acid attack. It was surprising, but reproducible, that these exceptionally fine layers (corresponding to roughly 2, 20 and 200 molecular layers, should confer good resistance to concentrated acid.
The oocysts recoveries from distilled water using the standard Cryptosporidium assay described in PCT/GB2006/001896 were as follows: untreated (i.e. no silica layer): 79.3%; microspheres with nominally 6Onm, 6 nm and 0.6 nm thick silica: 63. 6%, 65.2% and 72.3%, respectively. These results are interpreted was follows: Relative to the uncoated control, recovered yields decrease as the thickness of the silica layer increases.
This result is interpreted in terms of a smoothing out of the surface of the microsphere as the thickness of the layer increases. The decreasing recoveries of oocysts is intrepted as being due to loss of surface are per microsphere, and hence of total surface area, under the conditions of the assay (constant mass of microspheres added). In the oocyst assay that the silica layer confers the advantage that it prevents the magnetite from being dissolved off the microsphere at the acid wash stage which is used to separate the oocyts from the microspheres prior to the oocyst count. Therefore it is clear from this kind of experiment that there is an optimum silica layer thickness: one that imparts maximum acid- protection of the underlying magnetite layer, without unduly compromising the performance of the microsphere due to loss of surface area.
Claims (1)
- 40/65096GB2 391) A microsphere comprising a core, a functional layer and a solid oxide coating, wherein the functional layer forms an intermediate layer between the core and the solid oxide coating.2) A microsphere as claimed in claim 1, further comprising a priming layer, wherein the priming layer forms an intermediate layer between the solid oxide coating and the functional layer.3) A microsphere as claimed in claim 2, further comprising a coupling agent which couples the functional layer to the priming layer.4) A microsphere as claimed in any of the preceding claims, further comprising an anchoring agent, wherein the functional layer is anchored to the core by binding to the anchoring agent.5) A microsphere as claimed in claim 4, wherein the * ** anchoring agent comprises a functional-layer binding agent ** which binds to the functional layer.6) A microsphere as claimed in claim 5, wherein the 25 anchoring agent further comprises a coupling agent which couples the functional-layer binding agent to the core.7) A microsphere as claimed in claim 5 or 6, wherein the II * functional layer binds directly to the functional-layer I * * a *.binding agent.8) A microsphere as claimed in claim 5 or 6, wherein the functional layer is coupled to the functional-layer binding agent by a coupling agent.9) A microsphere as claimed in any of the preceding claims, further comprising an effector agent, wherein the solid oxide coating forms an intermediate layer between the effector agent and the core.40/65096G52 40 10) A microsphere as claimed in claim 9, wherein the effector agent is coupled to the solid oxide coating by a coupling agent.11) A microsphere as claimed in any of the preceding claims, wherein the core comprises any of the following: a synthetic polymer, a natural polymer, a co-polymer, a block co-polymer, polymethylmethacrylic acid, a protein, a glass, a ceramic, a ceramic oxide, or any combination thereof.12) A microsphere as claimed in any of the preceding claims, wherein the functional layer comprises a magnetizable agent, a fluorescent agent, a coloured agent or a radioactive agent.13) A microsphere as claimed in claim 12, wherein the magnetizable agent comprises any of the following; a paramagnetic agent, a superparamagnetic agent, iron, nickel, iron oxide, a spinel ferrite, an alloy, or any combination thereof. * **14) A microsphere as claimed in claim 12, wherein the **S *,* fluorescent or coloured agent comprises a pigment, a paint, ink, polymeric organic pigments, prorphyrin, or any * S. * * S * 25 combination thereof.15) A microsphere as claimed in claim 12, wherein the : * * radioactive agent comprises iodine-125, iodine-13l, 555 * * palladium, radium, iridium, cecium or any combination * S S S ** thereof.16) A microsphere as claimed in any of the preceding claims, wherein the functional layer is laid down in the form of nanoparticles.17) A microsphere as claimed in any of claims 2 to 16, wherein the priming layer comprises any of the following; a synthetic polymer, polymethylmethacrylic acid, a co- polymer, a block co-polymer, a natural polymer, a protein, 40/65096GB2 41 a peptide, an amino acid, or any combination thereof.18) A microsphere as claimed in any of claims 5 to 17, wherein the functional-layer binding agent comprises any of the following; a synthetic polymer, polymethylmethacrylic acid, a co-polymer, a block co- polymer, a natural polymer, a protein, a peptide, an amino acid, gelatine, a serum albumin, or any combination thereof.19) A microsphere as claimed in any of the previous claims, wherein the solid oxide coating comprises an oxide of aluminium, titanium, silicon, magnesium, zirconium, or any combination thereof.20) A microsphere as claimed in any of the preceding claims, wherein the solid oxide coating coats from 95 to 100% of the surface area of the microsphere.21) A microsphere as claimed in any of claims 3 to 20, wherein said coupling agent is a silane, a germane, or a mixture thereof. *22) A microsphere as claimed in any of claims 9 to 21, * wherein the effector agent comprises any of the following; a protein, an antibody, a lectin, an enzyme, a polypeptide, 25 a nucleotide, a polynucleotide, a polysaccharide, a metal- its ion sequestering agent, biotin, avidin, or any combination thereof. * S iii S23) A microsphere as claimed in any of the preceding * * * * claims, wherein the microsphere is a buoyant microsphere.24) A method for preparing a microsphere comprising the steps of depositing a functional layer on a microsphere core prior to coating the microsphere with a solid oxide.25) A method as claimed in claim 24, wherein the step of depositing the functional layer is carried out by: electrolytic deposition, chemical precipitation, chemical bonding, spray drying or vapour phase coating.40/65096GB2 42 26) A method as claimed in claim 24 or 25, wherein the step of applying the solid oxide coating is carried out by chemical precipitation.27) A method as claimed in claim 26, wherein the precipitation reaction is carried out by adding a solid oxide precursor to a mixture of microspheres and a hardener in a solvent system.28) A method as claimed in claim 27, wherein the solid oxide precursor is tetraethoxytitania, tetraethoxysilane, or a combination thereof.29) A method as claimed in claim 27, wherein the solvent system comprises isopropanol, methanol, ethanol, butanol, or any combination thereof.30) A method as claimed in claim 27 wherein the hardener is ammonia.31) A method as claimed in claim 30, wherein the concentration of ammonia is not less than 3 mol per litre * ** of reaction mixture. I...32) A method as claimed in any of claims 24 to 31, further * comprising the step of applying a priming layer to the 25 microsphere as an intermediate step between the steps of * depositing a functional layer and coating with a solid * . oxide. * I S 00 IS. * 33) A method as claimed in any of claims 24-32, further * S * * 00 comprising the step of chemically modifying the surface of a core prior to the step of depositing the functional layer onto the core.34) A method as claimed in claim 33, wherein the chemical modification comprises the step of anchoring a functional- layer binding agent to the core.35) A method as claimed in claim 34, wherein the anchoring of the functional-layer binding agent comprises the step of 40/65096G52 43 binding a coupling agent to the core.36) A method as claimed in claim 35, wherein the anchoring of the functional-layer binding agent further comprises the step of binding the functional-layer binding agent to the coupling agent.37) A method as claimed in any of claims 34 to 36, wherein the functional layer binds directly to the functional-layer binding agent.38) A method as claimed in any of claims 34 to 36, wherein the step of anchoring the functional layer to the core further comprises the step of coupling the functional layer to the functional-layer binding agent by a second coupling agent.39) A method as claimed in any of claims 32 to 38, further comprising the step of coupling the functional layer to the priming layer by a coupling agent.40) A method as claimed in any of claims 24 to 39, further * comprising the step of anchoring an effector agent to the **S* solid oxide coating.* 41) A method as claimed in claim 40, wherein the step of * S * * 25 anchoring the effector agent comprises the step of coupling S. S * the effector agent to the solid oxide coating by a coupling : * * agent.S42) A method as claimed in any of claims 24 to 41, wherein * S SSthe core comprises any of the following; a synthetic polymer, a natural polymer, a co-polymer, a block co- polymer, polymethylmethacrylc acid, a protein, a glass, a ceramic, a ceramic oxide, or any combination thereof.43) A method as claimed in any of claims 24 to 42, wherein the functional layer comprises a magnetizable agent, a coloured agent, a fluorescent agent or a radioactive agent.44) A method as claimed in any of claims 33 to 43, wherein 40/65096GB2 44 the priming layer comprises any of the following; a synthetic polymer, polyrnethylmethacrylic acid, a co- polymer, a block co-polymer, a natural polymer, a protein, a peptide, an amino acid, or any combination thereof.45) A method as claimed in any of claims 34 to 44, wherein the functionallayer binding agent comprises any of the following; a synthetic polymer, polymethylmethacrylic acid, a co-polymer, a block co-polymer, a natural polymer, a protein, a peptide, an amino acid, or any combination thereof.46) A method as claimed in any of claims 24 to 45, wherein the solid oxide coating comprises an oxide of aluminium, titanium, silicon, magnesium, zirconium, or any combination thereof.47) A method as claimed in any of claims 24 to 46, wherein the solid oxide coating coats from 95 to 100% of the surface area of the microsphere.48) A method as claimed in claim 35 to 47, wherein said coupling agent is a silane, a germane, or a mixture thereof.49) A method as claimed in any of claims 40 to 48, wherein the effector agent comprises any of the following; a protein, an antibody, a lectin, an enzyme, a polypeptide, a nucleotide, a polynucleotide, a polysaccharide, a metal-ion sequestering agent, biotin, avidin, or any combination thereof.50) A microsphere as claimed in any of the preceding claims, comprising a solid oxide coating with a thickness of from 0.2 to loonm.51) A multitude of microspheres, consisting or comprising a population of microspheres as claimed in and/or prepared by the methods as claimed in any of claims 1 to 50.40/65096GB2 45 52) A microsphere prepared according to any of the methods claimed in claims 24 to 49.53) A method as claimed in any of claims 24 to 49, wherein the microsphere prepared by any such method is a microsphere as claimed in any one of claims 1-23 and 50.53) A composition comprising a microsphere as claimed in any of claims 123 and 50 and a binder.54) A pharmaceutical composition comprising a microsphere according to the any of claims 1-23 and 50.55) A composition comprising a microsphere according to any of claims 123 and 50 for use in a method of treatment.56) A method for preparing a microsphere substantially as hereinbefore described.57) A microsphere according to claim 1, and substantially as hereinbefore described.58) A composition according to any of claims 53 to 55, and substantially as hereinbefore described. * a. * . * *1Se * S *SSS * .5 * S * * a. *5* * S $ S SXIS SS * S S * S.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0512374.0A GB0512374D0 (en) | 2005-06-17 | 2005-06-17 | Coated microspheres |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0612104D0 GB0612104D0 (en) | 2006-07-26 |
GB2427157A true GB2427157A (en) | 2006-12-20 |
Family
ID=34855722
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0512374.0A Ceased GB0512374D0 (en) | 2005-06-17 | 2005-06-17 | Coated microspheres |
GBGB0612106.5A Pending GB0612106D0 (en) | 2005-06-17 | 2006-06-19 | Coated microspheres |
GB0612104A Withdrawn GB2427157A (en) | 2005-06-17 | 2006-06-19 | Coated microspheres |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0512374.0A Ceased GB0512374D0 (en) | 2005-06-17 | 2005-06-17 | Coated microspheres |
GBGB0612106.5A Pending GB0612106D0 (en) | 2005-06-17 | 2006-06-19 | Coated microspheres |
Country Status (2)
Country | Link |
---|---|
GB (3) | GB0512374D0 (en) |
WO (1) | WO2007036682A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101439935B (en) * | 2008-12-22 | 2011-04-13 | 北京航空航天大学 | Preparation of hollow glass microsphere / ferrite composite material |
EP2733959A1 (en) * | 2011-07-13 | 2014-05-21 | Panasonic Corporation | Method for manufacturing acoustic matching body, acoustic matching body, ultrasonic transducer using acoustic matching body, and ultrasonic flowmeter |
US8802750B2 (en) | 2008-01-07 | 2014-08-12 | Ppg Industries Ohio, Inc. | Reduced density opaque coatings and aerospace vehicles at least partially coated therewith |
WO2015091745A1 (en) * | 2013-12-20 | 2015-06-25 | Sicpa Holding Sa | Thermoluminescent composite particle and marking comprising same |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102151527B (en) * | 2010-11-23 | 2013-05-15 | 苏州照康生物技术有限公司 | Preparation method of monodisperse silicon oxide magnetic microspheres used for DNA purification and protein separation |
PL3038115T3 (en) | 2011-08-10 | 2020-11-02 | Magforce Ag | Method of manufacturing agglomerating magnetic alkoxysilane-coated nanoparticles |
CN102676157B (en) * | 2012-05-15 | 2014-07-09 | 泰普生物科学(中国)有限公司 | Fluorescent microsphere marker and preparation method thereof |
BR112017027367B1 (en) * | 2015-06-18 | 2022-08-02 | Sicpa Holding Sa | COMPOUND PARTICLE, PLURALITY OF COMPOUND PARTICLES, MARKING COMPRISING THEM AND ARTICLE HAVING MARKING IN IT |
CN104940962B (en) * | 2015-07-03 | 2018-08-21 | 中国科学技术大学 | It is a kind of125I radiates microballoon, preparation method and microfluidic device |
CN110759745B (en) * | 2018-07-27 | 2022-02-15 | 广东清大同科环保技术有限公司 | High-strength cavity ceramsite and preparation method thereof |
CN110639056B (en) * | 2019-09-17 | 2021-12-17 | 天津理工大学 | Preparation method of medical magnesium alloy surface drug release functional coating |
CN110683860B (en) * | 2019-11-18 | 2021-10-22 | 萍乡学院 | Ceramic hollow ball with double-shell structure and preparation method thereof |
CN111957275A (en) * | 2020-08-07 | 2020-11-20 | 常熟理工学院 | Safe and environment-friendly indene dione display agent nanocapsule and preparation method and application thereof |
CN113304700B (en) * | 2021-06-11 | 2023-06-02 | 上海科技大学 | Method for preparing magnetic polymer microsphere and application thereof |
CN113413839B (en) * | 2021-07-07 | 2022-04-05 | 西南交通大学 | Salt response polyaniline microcapsule, self-warning coating and preparation method |
CN113578214B (en) * | 2021-08-11 | 2023-08-11 | 天津博蕴纯化装备材料科技有限公司 | Micron-sized porous magnetic microsphere and preparation method and application thereof |
CN116144220B (en) * | 2023-02-07 | 2024-01-02 | 北京石油化工学院 | Low-density solid flame-retardant buoyancy material and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474852A (en) * | 1983-05-23 | 1984-10-02 | Thomas B. Crane | Hydrophobic colloidal oxide treated core material, method of production and composition comprised thereof |
JPS62146962A (en) * | 1985-12-20 | 1987-06-30 | Teikoku Kako Kk | Iron oxide-coated inorganic sphere |
WO1998012717A1 (en) * | 1996-09-20 | 1998-03-26 | Merck Patent Gmbh | Spherical magnetic particles |
US6110528A (en) * | 1998-07-02 | 2000-08-29 | Agency Of Industrial Science And Technology | Method for the preparation of fine hollow glass spheres coated with titanium oxide |
US6685966B1 (en) * | 1998-02-13 | 2004-02-03 | Rhodia Chimie | Composite particles containing an active substance |
JP2005120187A (en) * | 2003-10-15 | 2005-05-12 | Mitsui Mining & Smelting Co Ltd | Black pigment particle |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1582956A (en) * | 1976-07-30 | 1981-01-21 | Ici Ltd | Composite magnetic particles |
EP0972563A1 (en) * | 1998-07-15 | 2000-01-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates |
-
2005
- 2005-06-17 GB GBGB0512374.0A patent/GB0512374D0/en not_active Ceased
-
2006
- 2006-06-19 GB GBGB0612106.5A patent/GB0612106D0/en active Pending
- 2006-06-19 WO PCT/GB2006/002224 patent/WO2007036682A1/en active Application Filing
- 2006-06-19 GB GB0612104A patent/GB2427157A/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474852A (en) * | 1983-05-23 | 1984-10-02 | Thomas B. Crane | Hydrophobic colloidal oxide treated core material, method of production and composition comprised thereof |
JPS62146962A (en) * | 1985-12-20 | 1987-06-30 | Teikoku Kako Kk | Iron oxide-coated inorganic sphere |
WO1998012717A1 (en) * | 1996-09-20 | 1998-03-26 | Merck Patent Gmbh | Spherical magnetic particles |
US6685966B1 (en) * | 1998-02-13 | 2004-02-03 | Rhodia Chimie | Composite particles containing an active substance |
US6110528A (en) * | 1998-07-02 | 2000-08-29 | Agency Of Industrial Science And Technology | Method for the preparation of fine hollow glass spheres coated with titanium oxide |
JP2005120187A (en) * | 2003-10-15 | 2005-05-12 | Mitsui Mining & Smelting Co Ltd | Black pigment particle |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8802750B2 (en) | 2008-01-07 | 2014-08-12 | Ppg Industries Ohio, Inc. | Reduced density opaque coatings and aerospace vehicles at least partially coated therewith |
CN101439935B (en) * | 2008-12-22 | 2011-04-13 | 北京航空航天大学 | Preparation of hollow glass microsphere / ferrite composite material |
EP2733959A1 (en) * | 2011-07-13 | 2014-05-21 | Panasonic Corporation | Method for manufacturing acoustic matching body, acoustic matching body, ultrasonic transducer using acoustic matching body, and ultrasonic flowmeter |
EP2733959A4 (en) * | 2011-07-13 | 2014-12-24 | Panasonic Corp | Method for manufacturing acoustic matching body, acoustic matching body, ultrasonic transducer using acoustic matching body, and ultrasonic flowmeter |
WO2015091745A1 (en) * | 2013-12-20 | 2015-06-25 | Sicpa Holding Sa | Thermoluminescent composite particle and marking comprising same |
AU2014368623B2 (en) * | 2013-12-20 | 2018-02-01 | Sicpa Holding Sa | Thermoluminescent composite particle and marking comprising same |
RU2647025C2 (en) * | 2013-12-20 | 2018-03-13 | Сикпа Холдинг Са | Thermoluminescent composite particle and marking containing it |
US11719644B2 (en) | 2013-12-20 | 2023-08-08 | Sicpa Holding Sa | Thermoluminescent composite particle and marking comprising same |
Also Published As
Publication number | Publication date |
---|---|
WO2007036682A1 (en) | 2007-04-05 |
GB0612104D0 (en) | 2006-07-26 |
GB0512374D0 (en) | 2005-07-27 |
GB0612106D0 (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2427157A (en) | Coated microspheres | |
Sonmez et al. | Synthesis and applications of Fe3O4/SiO2 core-shell materials | |
US10864270B2 (en) | Nanostructured carriers for guided and targeted on-demand substance delivery | |
US9675953B2 (en) | Encapsulated particles | |
US6479146B1 (en) | Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates | |
US20060105170A1 (en) | Magnetic particle and process for preparation | |
KR100845008B1 (en) | Silica Capsules Having Nano-Holes or Nano-Pores on Their Surfaces and Method for Preparing the Same | |
US6833192B1 (en) | Encapsulation of crystals via multilayer coatings | |
US20120283379A1 (en) | Silica particle including a molecule of interest, method for preparing same and uses thereof | |
CN1229305C (en) | Method for preparing ferrite/silicon dioxide core-shell nano particles by using ultrasonic treatment | |
JP2003533363A (en) | Coated nanoparticles | |
Dembski et al. | Core-shell nanoparticles and their use for in vitro and in vivo diagnostics | |
Wang et al. | Synthesis of hierarchical nickel anchored on Fe 3 O 4@ SiO 2 and its successful utilization to remove the abundant proteins (BHb) in bovine blood | |
Nakamura et al. | Preparation of hybrid hollow capsules formed with Fe3O4 and polyelectrolytes via the layer-by-layer assembly and the aqueous solution process | |
Boissiere et al. | Potentialities of silica/alginate nanoparticles as hybrid magnetic carriers | |
Maurizi et al. | Syntheses of cross-linked polymeric superparamagnetic beads with tunable properties | |
RU2583022C2 (en) | Method of producing nanocomposites based on gold nanoparticles coated with shell made of silicon oxide and quantum dots | |
WO2006125978A2 (en) | Assay particles | |
Liu et al. | Preparation of CdTe nanocrystals doped fluorescent silica spheres by sol-gel method and their surface modification via thiol-ene chemistry | |
Ornelas et al. | Synthesis and applications of templated sol-gel microspheres | |
Li et al. | Synthesis of γ-Fe 2 O 3/SiO 2/Au magnetic composites for immobilization of bovine serum albumin | |
Dembski et al. | use for in vitro and in vivo | |
CN118501461A (en) | CD38 monoclonal antibody-MOFs composite biological material and kit | |
Peng et al. | GoldMag composite particles and their applications in nanomedicine | |
CN116218512A (en) | Kiwi fruit-shaped magnetic fluorescent nanoparticle and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |